Expert recommendations for treating vitiligo in young patients in the US emphasize evidence-based approaches. Recommendations include topical corticosteroids, calcineurin inhibitors, and Janus kinase inhibitors. Specific guidance is provided for dosing, duration, and age considerations. Topical calcineurin inhibitors and corticosteroids are highlighted as first-line therapies, with ruxolitinib identified for nonsegmental vitiligo in patients under 12. The coordinated use of UV therapy is advised to prevent recurrence. These findings underscore the importance of tailored treatment strategies in pediatric and adolescent vitiligo management.
Like
Save
Share